Literature DB >> 11504469

Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Lee T. Bacheler1.   

Abstract

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a structurally diverse group of compounds which function as inhibitors of HIV-1 replication in vitro and in vivo. Viral resistance is mediated through alterations in the amino acids which form the allosteric site on the HIV-1 reverse transcriptase to which NNRTIs bind. The rapid emergence of resistant viruses has limited the utility of NNRTI monotherapy; however, recent clinical studies have shown that potent NNRTIs can contribute to profound suppression of HIV replication when used in combination therapy. An understanding of the development of resistance to NNRTIs is critical to the effective use of this class of antiretroviral agents. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Year:  1999        PMID: 11504469     DOI: 10.1054/drup.1998.0064

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  6 in total

1.  Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of residues L100, V106, and Y181 in the presence of nevirapine and efavirenz.

Authors:  Marilyn B Kroeger Smith; Lenea H Rader; Amanda M Franklin; Emily V Taylor; Katie D Smith; Richard H Smith; Julian Tirado-Rives; William L Jorgensen
Journal:  Bioorg Med Chem Lett       Date:  2007-12-23       Impact factor: 2.823

Review 2.  Delavirdine: a review of its use in HIV infection.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1.

Authors:  J W Corbett; S S Ko; J D Rodgers; S Jeffrey; L T Bacheler; R M Klabe; S Diamond; C M Lai; S R Rabel; J A Saye; S P Adams; G L Trainor; P S Anderson; S K Erickson-Viitanen
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Computational studies and drug design for HIV-1 reverse transcriptase inhibitors of 3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) analogs.

Authors:  Hai-Feng Chen; Bo-Tao Fan; Chen-Yang Zhao; Lan Xie; Chun-Hong Zhao; Ting Zhou; Kuo-Hsiung Lee; Graham Allaway
Journal:  J Comput Aided Mol Des       Date:  2005-04       Impact factor: 3.686

5.  Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.

Authors:  Yong Gao; Ellen Paxinos; Justin Galovich; Ryan Troyer; Heather Baird; Measho Abreha; Cissy Kityo; Peter Mugyenyi; Christos Petropoulos; Eric J Arts
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.

Authors:  Véronique Joly; Diane Descamps; Gilles Peytavin; Fatiha Touati; France Mentre; Xavier Duval; Séverine Delarue; Patrick Yeni; Françoise Brun-Vezinet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.